Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

XLO

Xilio Therapeutics (XLO)

Xilio Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XLO
DateTimeSourceHeadlineSymbolCompany
06/17/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
06/17/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
06/17/20244:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
06/13/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
06/13/20244:05PMGlobeNewswire Inc.Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of DirectorsNASDAQ:XLOXilio Therapeutics Inc
05/14/20248:09AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XLOXilio Therapeutics Inc
05/14/20247:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
05/14/20247:30AMGlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
05/07/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:XLOXilio Therapeutics Inc
04/01/20244:05PMGlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
03/28/20247:05AMGlobeNewswire Inc.Xilio Therapeutics Announces $11.3 Million Private Placement Equity FinancingNASDAQ:XLOXilio Therapeutics Inc
03/28/20247:00AMGlobeNewswire Inc.Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:XLOXilio Therapeutics Inc
03/28/20247:00AMBusiness WireGilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:XLOXilio Therapeutics Inc
02/28/20244:01PMGlobeNewswire Inc.Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care ConferenceNASDAQ:XLOXilio Therapeutics Inc
01/31/20244:01PMGlobeNewswire Inc.Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:XLOXilio Therapeutics Inc
01/19/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
01/08/20247:30AMGlobeNewswire Inc.Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology TherapiesNASDAQ:XLOXilio Therapeutics Inc
01/03/20244:38PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
01/03/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
01/03/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
01/03/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
12/07/20237:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
12/07/20237:30AMGlobeNewswire Inc.Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy DataNASDAQ:XLOXilio Therapeutics Inc
11/09/20234:17PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XLOXilio Therapeutics Inc
11/09/20234:13PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
11/09/20234:10PMEdgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
11/09/20234:08PMEdgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
11/09/20234:05PMEdgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
11/09/20234:01PMGlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
11/03/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:XLO